Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the treatment of moderate to severe VVC.

 

Condition Intervention Phase
Vulvovaginitis
Yeast Infection
Yeast Infection Vaginal
Candidiasis, Vulvovaginal
Drug: Oral Encochleated Amphotericin B (CAMB)
Drug: Fluconazole
Phase 2

 

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)

Antifungal name: 

Date of article/Start date of trial: 

Thursday, December 15, 2016

Trial phase: 

Phase 2

ClinicalTrials.gov ID: 

NCT02971007

Trial status: 

Active
New antifungal drugs